Mostrar el registro sencillo del ítem

dc.contributor.authorFábrega, María Josées_ES
dc.contributor.authorRodríguez-Nogales, Albaes_ES
dc.contributor.authorGarrido-Mesa, Josées_ES
dc.contributor.authorAlgieri, Francescaes_ES
dc.contributor.authorBadía, Josefaes_ES
dc.contributor.authorGiménez, Rosaes_ES
dc.contributor.authorGálvez Peralta, Julio Juan es_ES
dc.contributor.authorBaldomà, Lauraes_ES
dc.date.accessioned2018-02-15T10:14:08Z
dc.date.available2018-02-15T10:14:08Z
dc.date.issued2017-07-11
dc.identifier.citationFábrega, M.J.; et al. Intestinal Anti-inflammatory Effects of Outer Membrane Vesicles from Escherichia coli Nissle 1917 in DSS-Experimental Colitis in Mice. Frontiers in Microbiology, 8: 1274 (2017). [http://hdl.handle.net/10481/49559]es_ES
dc.identifier.issn1664-302X
dc.identifier.urihttp://hdl.handle.net/10481/49559
dc.description.abstractEscherichia coli Nissle 1917 (EcN) is a probiotic strain with proven efficacy in inducing and maintaining remission of ulcerative colitis. However, the microbial factors that mediate these beneficial effects are not fully known. Gram-negative bacteria release outer membrane vesicles (OMVs) as a direct pathway for delivering selected bacterial proteins and active compounds to the host. In fact, vesicles released by gut microbiota are emerging as key players in signaling processes in the intestinal mucosa. In the present study, the dextran sodium sulfate (DSS)-induced colitis mouse model was used to investigate the potential of EcN OMVs to ameliorate mucosal injury and inflammation in the gut. The experimental protocol involved pre-treatment with OMVs for 10 days before DSS intake, and a 5-day recovery period. Oral administration of purified EcN OMVs (5 μg/day) significantly reduced DSS-induced weight loss and ameliorated clinical symptoms and histological scores. OMVs treatment counteracted altered expression of cytokines and markers of intestinal barrier function. This study shows for the first time that EcN OMVs can mediate the anti-inflammatory and barrier protection effects previously reported for this probiotic in experimental colitis. Remarkably, translation of probiotics to human healthcare requires knowledge of the molecular mechanisms involved in probiotic–host interactions. Thus, OMVs, as a non-replicative bacterial form, could be explored as a new probiotic-derived therapeutic approach, with even lower risk of adverse events than probiotic administration.en
dc.description.sponsorshiphis work was funded by the “Ministerio de Economía y Competitividad”, Spain (Grants AGL2012-34985, AGL2016-79113-R (AEI/FEDER, UE) and AGL2015-67995-C3-3-R, all co-financed with European Commission ERDF funds), by the Generalitat de Catalunya, AGAUR (Grant 2014SGR1017), and by the Junta de Andalucía (Grant CTS-164). The CIBEREHD is funded by the Instituto de Salud Carlos III. M-JF acknowledges her FPI fellowship from the Spanish Ministry of Economy and Competitiveness.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es_ES
dc.subjectProbioticen_EN
dc.subjectEscherichia coli Nissie 1917en_EN
dc.subjectOuter membrane vesiclesen_EN
dc.subjectDSS-exprerimental colitisen_EN
dc.subjectMouse modelen_EN
dc.subjectImmune modulationen_EN
dc.titleIntestinal Anti-inflammatory Effects of Outer Membrane Vesicles from Escherichia coli Nissle 1917 in DSS-Experimental Colitis in Miceen_EN
dc.typejournal articleen_EN
dc.rights.accessRightsopen accessen_EN
dc.identifier.doi10.3389/fmicb.2017.01274


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Excepto si se señala otra cosa, la licencia del ítem se describe como Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License